J3R-MC-YDAL - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523659-73-00

Enrollment

167

Registered

2026-04-21

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight, Obesity

Brief summary

Percent Change from Baseline in Body Weight [Time Frame: Baseline, Week 64]

Interventions

DRUGPlacebo to match LY

DRUGEloralintide

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percent Change from Baseline in Body Weight [Time Frame: Baseline, Week 64]	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 22, 2026